64 related articles for article (PubMed ID: 27617402)
1. Inhibition of Bcl-2 family members sensitizes mesenchymal chondrosarcoma to conventional chemotherapy: report on a novel mesenchymal chondrosarcoma cell line.
de Jong Y; van Maldegem AM; Marino-Enriquez A; de Jong D; Suijker J; Briaire-de Bruijn IH; Kruisselbrink AB; Cleton-Jansen AM; Szuhai K; Gelderblom H; Fletcher JA; Bovée JV
Lab Invest; 2016 Oct; 96(10):1128-37. PubMed ID: 27617402
[TBL] [Abstract][Full Text] [Related]
2. Detection of mesenchymal chondrosarcoma in pleural effusion with immunocytochemistry and determination of HEY1::NCOA2 fusion by next-generation sequencing on cell block.
Zhong J; Wang Q; Xie Y; Niu Z; Zhou D
Cytopathology; 2024 Jan; 35(1):149-152. PubMed ID: 37688410
[TBL] [Abstract][Full Text] [Related]
3. Response of conventional chondrosarcoma to gemcitabine alone: a case report.
Provenzano S; Hindi N; Morosi C; Ghilardi M; Collini P; Casali PG; Stacchiotti S
Clin Sarcoma Res; 2015; 5():9. PubMed ID: 25793102
[TBL] [Abstract][Full Text] [Related]
4. p160 nuclear receptor coactivator family members and their role in rare fusion‑driven neoplasms (Review).
Segovia D; Tepes PS
Oncol Lett; 2024 May; 27(5):210. PubMed ID: 38572059
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Chondrosarcoma from Diagnosis to Clinical Trials.
Dudzisz-Śledź M; Kondracka M; Rudzińska M; Zając AE; Firlej W; Sulejczak D; Borkowska A; Szostakowski B; Szumera-Ciećkiewicz A; Piątkowski J; Rutkowski P; Czarnecka AM
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760551
[TBL] [Abstract][Full Text] [Related]
6. MiR-4270 acts as a tumor suppressor by directly targeting Bcl-xL in human osteosarcoma cells.
Veys C; Boulouard F; Benmoussa A; Jammes M; Brotin E; Rédini F; Poulain L; Gruchy N; Denoyelle C; Legendre F; Galera P
Front Oncol; 2023; 13():1220459. PubMed ID: 37719019
[TBL] [Abstract][Full Text] [Related]
7. Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis.
Qi W; Rosikiewicz W; Yin Z; Xu B; Jiang H; Wan S; Fan Y; Wu G; Wang L
J Pathol; 2022 Aug; 257(5):579-592. PubMed ID: 35342947
[TBL] [Abstract][Full Text] [Related]
8. Patient-derived xenografts and in vitro model show rationale for imatinib mesylate repurposing in HEY1-NCoA2-driven mesenchymal chondrosarcoma.
Safaric Tepes P; Segovia D; Jevtic S; Ramirez D; Lyons SK; Sordella R
Lab Invest; 2022 Sep; 102(9):1038-1049. PubMed ID: 34837064
[TBL] [Abstract][Full Text] [Related]
9. Tumor Suppressive Role of miR-342-5p in Human Chondrosarcoma Cells and 3D Organoids.
Veys C; Benmoussa A; Contentin R; Duchemin A; Brotin E; Lafont JE; Saintigny Y; Poulain L; Denoyelle C; Demoor M; Legendre F; Galéra P
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070455
[TBL] [Abstract][Full Text] [Related]
10. Selection of Effective Therapies Using Three-Dimensional
Palubeckaitė I; Venneker S; Briaire-de Bruijn IH; van den Akker BE; Krol AD; Gelderblom H; Bovée JVMG
Front Mol Biosci; 2020; 7():566291. PubMed ID: 33425984
[No Abstract] [Full Text] [Related]
11. Beyond the Influence of
Venneker S; Kruisselbrink AB; Baranski Z; Palubeckaite I; Briaire-de Bruijn IH; Oosting J; French PJ; Danen EHJ; Bovée JVMG
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33266275
[TBL] [Abstract][Full Text] [Related]
12. Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines.
Abdul Rahman SF; Muniandy K; Soo YK; Tiew EYH; Tan KX; Bates TE; Mohana-Kumaran N
Biochem Biophys Rep; 2020 Jul; 22():100756. PubMed ID: 32346617
[TBL] [Abstract][Full Text] [Related]
13. A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival.
de Jong Y; Bennani F; van Oosterwijk JG; Alberti G; Baranski Z; Wijers-Koster P; Venneker S; Briaire-de Bruij IH; van de Akker BE; Baelde H; Cleton-Jansen AM; van de Water B; Danen EHJ; Bovée JVMG
J Bone Oncol; 2019 Dec; 19():100268. PubMed ID: 31832331
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the
Venneker S; Kruisselbrink AB; Briaire-de Bruijn IH; de Jong Y; van Wijnen AJ; Danen EHJ; Bovée JVMG
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31810230
[TBL] [Abstract][Full Text] [Related]
15. Robot-assisted radical nephrectomy for primary renal mesenchymal chondrosarcoma: case report and literature review.
Deng W; Zhou J; Liu X; Chen L; Guo G; Fu B
Ren Fail; 2019 Nov; 41(1):98-103. PubMed ID: 30909775
[TBL] [Abstract][Full Text] [Related]
16. Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway.
Addie RD; de Jong Y; Alberti G; Kruisselbrink AB; Que I; Baelde H; Bovée JVMG
J Bone Oncol; 2019 Apr; 15():100222. PubMed ID: 30766792
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma.
de Jong Y; Monderer D; Brandinelli E; Monchanin M; van den Akker BE; van Oosterwijk JG; Blay JY; Dutour A; Bovée JVMG
Oncogenesis; 2018 Sep; 7(9):74. PubMed ID: 30242253
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology.
El Beaino M; Roszik J; Livingston JA; Wang WL; Lazar AJ; Amini B; Subbiah V; Lewis V; Conley AP
Curr Oncol Rep; 2018 Mar; 20(5):37. PubMed ID: 29582189
[TBL] [Abstract][Full Text] [Related]
19. Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation.
Peterse EFP; Niessen B; Addie RD; de Jong Y; Cleven AHG; Kruisselbrink AB; van den Akker BEWM; Molenaar RJ; Cleton-Jansen AM; Bovée JVMG
Br J Cancer; 2018 Apr; 118(8):1074-1083. PubMed ID: 29576625
[TBL] [Abstract][Full Text] [Related]
20. GABA
Kanbara K; Otsuki Y; Watanabe M; Yokoe S; Mori Y; Asahi M; Neo M
BMC Cancer; 2018 Mar; 18(1):263. PubMed ID: 29514603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
